Point-of-Care Peptide Hormone Production Enabled by Cell-Free Protein Synthesis

Area of Science:

• Biotechnology
• Pharmaceutical Sciences
• Molecular Biology

Background:

• Biologic medicines, particularly peptide hormones, face delivery challenges in resource-limited settings due to cold chain and infrastructure issues.
• Decentralized manufacturing, such as point-of-care production, could address these limitations by enabling local, on-demand drug synthesis.

Purpose of the Study:

• To develop a novel platform for point-of-care drug manufacturing by integrating cell-free protein synthesis (CFPS) with a streamlined purification and cleavage process.
• To demonstrate the platform's capability by synthesizing a panel of peptide hormones, crucial for treating diseases like diabetes and growth disorders.

Main Methods:

• Combined cell-free protein synthesis (CFPS) with a 2-in-1 affinity purification and enzymatic cleavage strategy.
• Utilized temperature-stable lyophilized CFPS components, rehydrated with DNA encoding SUMOylated peptide hormones.
• Employed Strep-Tactin affinity purification followed by on-bead SUMO protease cleavage to obtain native peptide hormones.

Main Results:

• Successfully synthesized a panel of peptide hormones using the developed point-of-care manufacturing platform.
• The produced peptide hormones were in their native form, validated by ELISA antibody recognition and receptor binding assays.
• Demonstrated the potential for on-demand, localized production of therapeutic peptides.

Conclusions:

• The integrated CFPS and purification platform shows promise for decentralized, point-of-care manufacturing of peptide hormone drugs.
• This approach could overcome critical cold chain and infrastructure barriers for biologic medicine delivery.
• Further development is needed to ensure biologic activity and patient safety for clinical application.